1
/
of
1
Springer US
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on New Drugs #x00026; Devices, October 27 #x00026; 28, 1988
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on New Drugs #x00026; Devices, October 27 #x00026; 28, 1988
Regular price
$319.00 USD
Regular price
Sale price
$319.00 USD
Shipping calculated at checkout.
Quantity
Couldn't load pickup availability
Share
